These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33269511)

  • 1. Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF
    Elharram M; Ferreira JP; Huynh T; Ni J; Giannetti N; Verma S; Zannad F; Sharma A
    Diabetes Obes Metab; 2021 Mar; 23(3):782-790. PubMed ID: 33269511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the WATCH-DM and TRS-HF
    Segar MW; Patel KV; Hellkamp AS; Vaduganathan M; Lokhnygina Y; Green JB; Wan SH; Kolkailah AA; Holman RR; Peterson ED; Kannan V; Willett DL; McGuire DK; Pandey A
    J Am Heart Assoc; 2022 Jun; 11(11):e024094. PubMed ID: 35656988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial.
    Razaghizad A; Sharma A; Ni J; Ferreira JP; White WB; Mehta CR; Bakris GL; Zannad F
    Diabetes Obes Metab; 2023 Jan; 25(1):229-237. PubMed ID: 36082521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
    Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk.
    Khan MS; Segar MW; Usman MS; Patel KV; Van Spall HGC; DeVore AD; Vaduganathan M; Lam CSP; Zannad F; Verma S; Butler J; Tang WHW; Pandey A
    JACC Heart Fail; 2023 Jul; 11(7):825-835. PubMed ID: 37227388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score.
    Lin Y; Shao H; Shi L; Anderson AH; Fonseca V
    Diabetes Obes Metab; 2022 Nov; 24(11):2203-2211. PubMed ID: 35801340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score.
    Segar MW; Vaduganathan M; Patel KV; McGuire DK; Butler J; Fonarow GC; Basit M; Kannan V; Grodin JL; Everett B; Willett D; Berry J; Pandey A
    Diabetes Care; 2019 Dec; 42(12):2298-2306. PubMed ID: 31519694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.
    Bergmark BA; Bhatt DL; Braunwald E; Morrow DA; Steg PG; Gurmu Y; Cahn A; Mosenzon O; Raz I; Bohula E; Scirica BM
    Diabetes Care; 2018 Mar; 41(3):577-585. PubMed ID: 29196298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.
    Stevens SR; Segar MW; Pandey A; Lokhnygina Y; Green JB; McGuire DK; Standl E; Peterson ED; Holman RR
    Cardiovasc Diabetol; 2022 Aug; 21(1):166. PubMed ID: 36030198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention.
    Zafrir B; Adawi S; Khalaily M; Jaffe R; Eitan A; Barnett-Griness O; Saliba W
    J Am Heart Assoc; 2019 Jul; 8(14):e012433. PubMed ID: 31271083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry.
    Johnson LSB; Oldgren J; Barrett TW; McNaughton CD; Wong JA; McIntyre WF; Freeman CL; Murphy L; Engström G; Ezekowitz M; Connolly SJ; Xu L; Nakamya J; Conen D; Bangdiwala SI; Yusuf S; Healey JS
    J Am Heart Assoc; 2021 Sep; 10(18):e017735. PubMed ID: 34514842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial.
    Patel KV; Khan MS; Segar MW; Bahnson JL; Garcia KR; Clark JM; Balasubramanyam A; Bertoni AG; Vaduganathan M; Farkouh ME; Januzzi JL; Verma S; Espeland M; Pandey A
    Eur J Heart Fail; 2022 Nov; 24(11):2037-2047. PubMed ID: 36280384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
    Udell JA; Bhatt DL; Braunwald E; Cavender MA; Mosenzon O; Steg PG; Davidson JA; Nicolau JC; Corbalan R; Hirshberg B; Frederich R; Im K; Umez-Eronini AA; He P; McGuire DK; Leiter LA; Raz I; Scirica BM;
    Diabetes Care; 2015 Apr; 38(4):696-705. PubMed ID: 25552421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus.
    Yang X; Ma RC; So WY; Kong AP; Ko GT; Ho CS; Lam CW; Cockram CS; Tong PC; Chan JC
    Cardiovasc Diabetol; 2008 Apr; 7():9. PubMed ID: 18430204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptation of risk prediction equations for cardiovascular outcomes among patients with type 2 diabetes in real-world settings: a cross-institutional study using common data model approach.
    Yang CT; Chong KS; Wang CC; Ou HT; Kuo S
    Cardiovasc Diabetol; 2024 Jul; 23(1):244. PubMed ID: 38987773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and predictors of heart failure disease management referral in patients hospitalized with heart failure: insights from the Get With the Guidelines Program.
    Gharacholou SM; Hellkamp AS; Hernandez AF; Peterson ED; Bhatt DL; Yancy CW; Fonarow GC
    J Card Fail; 2011 May; 17(5):431-9. PubMed ID: 21549302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Sattar N; McMurray J; Borén J; Rawshani A; Omerovic E; Berg N; Halminen J; Skoglund K; Eliasson B; Gerstein HC; McGuire DK; Bhatt D; Rawshani A
    Circulation; 2023 Jun; 147(25):1872-1886. PubMed ID: 37154040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.